Selective, physiology-informed intervention outperforms routine intervention
For the many patients who arrive at cardiac intervention carrying both a failing aortic valve and obstructed coronary arteries, medicine has long faced an unanswered question: which blockages truly demand repair, and which are better left alone? A new meta-analysis presented at EuroPCR 2026 offers a clarifying answer — that measuring whether a blockage actually restricts blood flow, rather than simply observing how it looks, reduces serious cardiac events by nearly half. In an era of increasingly precise medicine, the study affirms that seeing is not always knowing, and that acting on physiology rather than appearance may be the more humane path.
- Half of all TAVI patients also carry coronary artery disease, and the field has lacked clear guidance on whether to intervene — creating a high-stakes clinical ambiguity affecting thousands annually.
- The ARTICA meta-analysis pooled 1,050 patients across four randomized trials, directly pitting physiology-guided, angiography-guided, and medication-only strategies against one another.
- FFR-guided intervention — targeting only blockages proven to restrict blood flow — cut major adverse cardiac events by 42% compared to medication alone, while angiography-guided intervention offered no measurable benefit over doing nothing.
- Routine visual-based intervention not only failed to improve outcomes but exposed patients to higher bleeding rates, suggesting indiscriminate treatment may cause net harm.
- The findings are positioned as late-breaking trials at EuroPCR 2026, signaling that clinical practice guidelines for TAVI candidates with coronary disease may soon be rewritten around precision physiology.
Three landmark trials are poised to reshape how cardiologists approach a persistent clinical dilemma: what to do about blocked coronary arteries in patients who also need a new aortic valve. The European Society of Cardiology selected these studies as late-breaking trials for EuroPCR 2026 — a designation that signals meaningful change is coming.
Severe aortic stenosis drives thousands of patients each year toward transcatheter aortic valve implantation, or TAVI, a minimally invasive procedure now considered standard care. But roughly half of these patients also have coronary artery disease. The unresolved question: should those blockages be fixed alongside the valve procedure, or managed with medication alone?
The ARTICA meta-analysis, led by Roberto Scarsini, pooled data from four randomized trials and 1,050 patients, dividing them into three groups — those who received physiology-guided intervention using fractional flow reserve (FFR), those treated based on conventional angiography, and those managed with medication only.
The results were decisive in their distinctions. FFR-guided intervention, which targets only blockages confirmed to restrict blood flow, reduced major adverse cardiac events by 42% compared to medication alone — a statistically significant result. It also lowered bleeding complications, occurring in 8.2% of FFR patients versus 13.7% in the angiography group. Angiography-guided intervention, by contrast, offered no benefit over medication, suggesting that treating blockages based on appearance alone neither helps nor spares patients from procedural risk.
The broader takeaway is that precision matters more than action. When all PCI was considered together, outcomes improved by 30% over medication — but that advantage belonged almost entirely to the FFR-guided patients. For those facing TAVI, the study draws a meaningful line between care shaped by actual physiology and care shaped by what a blockage merely looks like.
Three landmark trials are about to reshape how cardiologists think about a common clinical puzzle: what to do about clogged coronary arteries in patients who need a new aortic valve. The question sounds narrow, but it affects thousands of people each year. The European Society of Cardiology selected these studies as late-breaking trials for EuroPCR 2026, the kind of designation that signals the cardiology world is about to shift.
The problem is straightforward enough. Severe aortic stenosis—a narrowing of the aortic valve that forces the heart to work harder—sends many patients to the catheterization lab for transcatheter aortic valve implantation, or TAVI, a minimally invasive procedure that has become standard care. But roughly half of these patients also have coronary artery disease, blockages in the vessels that feed the heart muscle itself. The question that has lingered without a clear answer: should doctors fix those blockages before or during the TAVI procedure, or should they skip intervention and manage the coronary disease with medication alone?
A new meta-analysis called ARTICA—Advanced Research on TAVI and Ischemia-guided Coronary Assessment—pooled data from four randomized controlled trials involving 1,050 patients to find out. The researchers, led by Roberto Scarsini, divided the patients into three groups: 439 received physiology-guided intervention using fractional flow reserve, or FFR, a measurement that tells doctors whether a blockage is actually limiting blood flow; 255 received intervention based on angiography alone, the traditional visual assessment; and 356 received medical management without any intervention.
The results favored precision over routine intervention. When doctors used FFR guidance to decide which blockages actually needed opening, patients had a 42 percent lower risk of major adverse cardiac events—death, heart attack, additional revascularization, or stroke—at one year compared with those treated with medication alone. The hazard ratio was 0.58, with a confidence interval of 0.37 to 0.91, a result that crossed the threshold of statistical significance. FFR-guided intervention also reduced the combined endpoint of major adverse events plus major bleeding, dropping the hazard ratio to 0.68.
Angiography-guided intervention, by contrast, showed no benefit over medical management. Patients who received intervention based on visual assessment of the coronary arteries had similar rates of adverse events as those who received only medication. This distinction matters enormously. It suggests that opening blockages indiscriminately—simply because they look significant on an angiogram—does not improve outcomes and may expose patients to unnecessary procedural risk.
When the researchers looked at all PCI together, regardless of guidance method, there was a 30 percent reduction in major adverse events compared with medical management alone, but this advantage was driven almost entirely by the FFR-guided group. Major bleeding occurred in 8.2 percent of patients who received FFR-guided intervention, compared with 13.7 percent in the angiography-guided group and 12.6 percent in the medical management group, suggesting that selective intervention based on physiology may also spare patients from bleeding complications.
The implication is clear: in patients with severe aortic stenosis and coronary disease undergoing TAVI, a strategy of selective, physiology-informed intervention outperforms both routine intervention and medical management alone. The findings suggest that clinical practice guidelines may soon shift toward recommending FFR assessment before deciding whether to intervene on coronary lesions in this population. For patients facing TAVI, it means the difference between a procedure tailored to their actual physiology and one based on appearance alone.
Notable Quotes
Physiology-guided PCI may improve the outcomes of patients with coronary artery disease undergoing TAVI, while routine PCI provides limited advantage compared with medical management alone.— EuroPCR Course Directors, based on ARTICA meta-analysis findings
The Hearth Conversation Another angle on the story
Why does it matter whether doctors use FFR or just look at the angiogram? Aren't they both ways of seeing the same blockage?
They're seeing the same anatomy, but FFR tells you whether that blockage is actually starving the heart of blood. A vessel can look 70 percent blocked on film and still deliver enough oxygen. FFR measures that directly. Angiography can't.
So doctors were opening arteries that didn't need opening?
Exactly. The angiography-guided group had the same outcomes as patients on medication alone. They went through the procedure, took on the bleeding risk, and gained nothing.
What changed between the trials that showed benefit and the ones that didn't?
The trials that favored intervention—NOTION-3 and FAITAVI—used FFR. The neutral ones used angiography or didn't use physiology guidance at all. It's the difference between precision and assumption.
Does this mean TAVI patients shouldn't get their coronaries fixed?
Not at all. It means fix the ones that matter. FFR-guided intervention cut major adverse events by 42 percent. But you have to measure first. That's the discipline the data is teaching us.